The Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment
2010年1月3日 更新者:Enzymotec
A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment
The primary objective of this trial is to assess the ability of an oral administration of Phosphatidylserine-Omega3 to improve attention and memory complaints in comparison to placebo in age associated memory impaired subjects.
研究概览
研究类型
介入性
注册 (实际的)
157
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Tel Aviv、以色列、64239
- The Tel Aviv Sourasky Medical Center, Neurology department
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
50年 至 90年 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
全部
描述
Inclusion Criteria:
- Ability to give written informed consent
- Age: 90≥ years ≥50
- Gender: male and female
- CDR ≤ 0.5
- Complaints of memory loss reflected in such everyday problems as difficulty remembering names of individuals following introduction, misplacing objects, difficulty remembering multiple items to be purchased or multiple tasks to be performed, difficulty remembering telephone numbers or zip codes, and difficulty recalling information quickly or following distraction. Onset of memory loss must be described as gradual, without sudden worsening in recent months. Complaints of memory loss to be assessed by the MAC-Q scale.
- Mini-Mental State Examination (MMSE) ≥27 for subjects with college education (BA) and ≥ 26 for all others
- Memory test performance that is at least 1 SD below the mean established for young adults on at least one neuropsychological subtest of NexAde.
- Language: Subjects must be able to read, write and speak Hebrew.
- Ability to perform tests and interviews
Exclusion Criteria:
- Evidence of delirium, confusion, or other disturbances of consciousness
- Any Neurological disorder that could produce cognitive deterioration. Such disorders include AD, Parkinson's disease, stroke, intracranial hemorrhage, local brain lesions including tumors, and normal pressure hydrocephalus
- History of any infective or inflammatory brain disease including those of viral, fungal, or syphilitic etiologies
- Evidence of significant cerebral vascular pathology
- Head injury immediately preceding cognitive deterioration.
- Current psychiatric diagnosis according to DSM IV criteria of depression, mania, or any other major psychiatric disorder
- Current diagnosis or history of alcoholism or drug dependence.
- Evidence of depression as determined by the Geriatric Depression Scale (short version) score of 5 or more.
- Any medical disorder that could produce cognitive deterioration including renal, respiratory, cardiac, and hepatic disease, diabetes mellitus, endocrine, metabolic or hematological disturbances unless well controlled, and malignancy not in remission for more than two years
- Use of psychotropic drug or any other drug or supplement that may significantly affect cognitive functioning during the month prior to psychometric testing.
- Use of any experimental medication within 1 month prior to screening or as concomitant medications.
- Subject has a history of hypersensitivity or allergy to fish or fish oil or soy.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:PS-Omega3
Phosphatidylserine-Omega3, 300mg/day 15 wk
|
Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk.
Next, follow up phase, open label,1x100mg/day, 15 wk
|
安慰剂比较:Placebo
Cellulose tainted with fishy odor, 3 capsules/day
|
Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Change From Baseline in Rey Auditory Verbal Learning Test
大体时间:baseline, 15 wk
|
A widely used, brief, easy to understand scale to evaluate verbal learning and memory.
The score is presented as the number of words correctly recalled (0 is worse, 15 is best).The total learning task score ranges from 0 to 45 words(0 is worse, 45 is best).
|
baseline, 15 wk
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Blood Work
大体时间:baseline,15 wk
|
baseline,15 wk
|
|
Trail Making Test
大体时间:Baseline, 15 weeks
|
Baseline, 15 weeks
|
|
Computerized Cognitive Assessment Tool
大体时间:baseline, 15 weeks
|
baseline, 15 weeks
|
|
Clinical Global Impression of Change (CGI-C)Scale
大体时间:7 weeks, 15 weeks
|
The Clinical Global Impression of Change (CGI-C)scale is designed to record the clinician's global impression of change.
Global improvement score ranges from 1 = "Very much improved", through 4 = "No change", to 7 = "Very much worse".
Participants who experienced an improvement (scores 1, 2 or 3) in at least one of the two visits (following 7 or 15 weeks of treatment) were classified as improved over the treatment period (with the exception of participants reporting improvement following 7 weeks and deterioration at endpoint, who were NOT rated as improved)
|
7 weeks, 15 weeks
|
Change From Baseline in Rey Osterrieth Complex Figure Test
大体时间:baseline, 15 weeks
|
A widely used neuropsychological tool for the evaluation of visuospatial constructional ability and visual memory.
Both the time to complete the task (copy time)and the accuracy (immediate and delayed recall) were used as measures for the analysis.
Accuracy range score is 0-36 points (0 is worse, 36 is best).
Copy time is expressed in seconds (less time to copy indicates better performance).
|
baseline, 15 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
调查人员
- 研究主任:Amos Korczyn, MD、Sourasky Medical Center
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2007年4月1日
初级完成 (实际的)
2008年6月1日
研究完成 (实际的)
2008年9月1日
研究注册日期
首次提交
2007年2月20日
首先提交符合 QC 标准的
2007年2月20日
首次发布 (估计)
2007年2月21日
研究记录更新
最后更新发布 (估计)
2010年1月5日
上次提交的符合 QC 标准的更新
2010年1月3日
最后验证
2010年1月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
PS-Omega3的临床试验
-
Canadian Radiostereometric Analysis NetworkDalhousie University; London Health Sciences Centre; Orthopaedic Innovation Centre完全的
-
Applied Science Private University完全的
-
Centre d'Etudes et de Recherche pour l'Intensification...Kerecis Ltd.; RCTs; Clininfo S.A.完全的